A Phase 3 Confirmatory Study Investigating the Efficacy and Safety of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis

Trial Profile

A Phase 3 Confirmatory Study Investigating the Efficacy and Safety of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis

Completed
Phase of Trial: Phase III

Latest Information Update: 05 Mar 2018

At a glance

  • Drugs Dupilumab (Primary)
  • Indications Atopic dermatitis
  • Focus Registrational; Therapeutic Use
  • Acronyms Liberty AD Solo 1; SOLO 1
  • Sponsors Regeneron Pharmaceuticals
  • Most Recent Events

    • 05 Mar 2018 Results of pooled analysis from 2 randomised phase III trials (LIBERTY AD SOLO 1 and 2) presented at the 2018 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
    • 05 Mar 2018 Results of subgroup analysis (patients with or without comorbid allergic rhinitis) assessing safety and efficacy of dupilumab using patient data from NCT02277743 & NCT02277769 trials presented at the 2018 Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
    • 05 Mar 2018 Results of pooled data from (LIBERTY AD SOLO 1&2: NCT02277743; NCT02277769) assessing efficacy and safety of dupilumab in adults with moderate-to-severe AD with or without patient-reported comorbid food allergy (FA), were presented at the 2018 Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top